Barclays PLC Atara Biotherapeutics, Inc. Transaction History

Barclays PLC

$288 Billion
Q1 2024

A detailed history of Barclays PLC transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Barclays PLC holds 67,661 shares of ATRA stock, worth $575,118. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,661

Previous 132,847 49.07%

Holding current value

$575,118

Previous $69,000 31.88%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.44 - $1.22 $28,681 - $79,526	-65,186 Reduced 49.07%	67,661 $47,000
Q4 2023 Feb 15, 2024	BUY	$0.23 - $1.74 $26,706 - $202,038	116,114 Added 693.92%	132,847 $69,000
Q3 2023 Nov 07, 2023	SELL	$1.41 - $2.31 $26,254 - $43,012	-18,620 Reduced 52.67%	16,733 $25,000
Q2 2023 Aug 03, 2023	SELL	$1.5 - $3.04 $547,815 - $1.11 Million	-365,210 Reduced 91.17%	35,353 $56,000
Q1 2023 May 04, 2023	BUY	$2.8 - $5.46 $316,783 - $617,728	113,137 Added 39.36%	400,563 $1.16 Million

Q4 2022 Feb 13, 2023	SELL	$2.85 - $5.18 $165,832 - $301,408	-58,187 Reduced 16.84%	287,426 $942,000
Q3 2022 Nov 03, 2022	BUY	$2.85 - $8.73 $923,437 - $2.83 Million	324,013 Added 1500.06%	345,613 $1.31 Million
Q2 2022 Aug 12, 2022	SELL	$4.69 - $9.84 $246,436 - $517,042	-52,545 Reduced 70.87%	21,600 $168,000
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $1.34 Million - $2.69 Million	-159,047 Reduced 68.2%	74,145 $688,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $1.03 Million - $1.39 Million	-69,991 Reduced 23.09%	233,192 $3.68 Million
Q3 2021 Nov 09, 2021	SELL	$11.99 - $17.9 $56,173 - $83,861	-4,685 Reduced 1.52%	303,183 $5.43 Million
Q2 2021 Aug 13, 2021	BUY	$12.89 - $16.58 $1.63 Million - $2.09 Million	126,247 Added 69.51%	307,868 $4.79 Million
Q1 2021 May 13, 2021	BUY	$14.0 - $20.72 $1.57 Million - $2.32 Million	112,048 Added 161.05%	181,621 $2.61 Million
Q4 2020 Feb 11, 2021	SELL	$12.67 - $26.23 $130,665 - $270,509	-10,313 Reduced 12.91%	69,573 $1.37 Million
Q3 2020 Nov 12, 2020	SELL	$11.92 - $15.87 $314,127 - $418,222	-26,353 Reduced 24.81%	79,886 $1.04 Million
Q2 2020 Aug 12, 2020	BUY	$7.53 - $14.93 $194,424 - $385,492	25,820 Added 32.11%	106,239 $1.55 Million
Q1 2020 May 13, 2020	BUY	$5.69 - $17.78 $82,704 - $258,432	14,535 Added 22.06%	80,419 $683,000
Q4 2019 Feb 10, 2020	BUY	$10.89 - $16.79 $311,454 - $480,194	28,600 Added 76.71%	65,884 $1.09 Million
Q3 2019 Nov 14, 2019	SELL	$12.03 - $19.94 $594,306 - $985,075	-49,402 Reduced 56.99%	37,284 $526,000
Q2 2019 Aug 14, 2019	BUY	$19.05 - $41.04 $1.38 Million - $2.97 Million	72,410 Added 507.21%	86,686 $1.74 Million
Q1 2019 May 15, 2019	SELL	$28.4 - $41.74 $768,049 - $1.13 Million	-27,044 Reduced 65.45%	14,276 $567,000
Q4 2018 Feb 14, 2019	BUY	$30.9 - $42.97 $773,334 - $1.08 Million	25,027 Added 153.61%	41,320 $1.44 Million
Q3 2018 Nov 14, 2018	BUY	$35.05 - $43.5 $466,690 - $579,202	13,315 Added 447.11%	16,293 $674,000
Q2 2018 Aug 14, 2018	SELL	$35.15 - $51.45 $197,543 - $289,149	-5,620 Reduced 65.36%	2,978 $110,000
Q1 2018 May 15, 2018	SELL	$18.0 - $48.35 $1,602 - $4,303	-89 Reduced 1.02%	8,598 $335,000
Q4 2017 Feb 14, 2018	SELL	$13.2 - $18.1 $95,634 - $131,134	-7,245 Reduced 45.47%	8,687 $158,000
Q3 2017 Nov 14, 2017	BUY	$13.25 - $17.05 $211,099 - $271,640	15,932	15,932 $264,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

85M

Call Options Held

18.4K

Put Options Held

51.3K

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $802M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account